An HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone

Author(s): Dimitris Kounatidis, Dimitra Rontogianni, Dimitrios Sampaziotis, Maria Vardaka, Chara Giatra, Christodoulos Dolapsakis, Evangelia Margellou, Natalia G. Vallianou*.

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 20 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Multicentric Castleman Disease (MCD) presents with enlarged lymph nodes in multiple regions and systemic inflammatory symptoms, due to the dysregulation of cytokines, most commonly interleukin-6 (IL-6). Human herpes virus-8 (HHV-8) is strongly related to MCD (HHV-8-associated MCD) and is being implicated in cytokine dysregulation in patients, the majority of whom are HIV positive or immunosuppressed. Preferred treatment of HHV-8- associated MCD depends on the presence or not of concurrent Kaposi sarcoma and on whether the patient has life-threatening organ failure or poor performance status thought to be related to HHV- 8-associated MCD.

Case Presentation: Herein, we describe a female patient with HHV-8 positive, HIV negative MCD, who responded well to the administration of rituximab once weekly for four weeks alone for three cycles.

Conclusion: HHV-8 positive, HIV negative MCD treatment modalities are only anecdotal due to the rarity of this form of MCD. Administration of rituximab alone seems to be beneficial among patients with good performance status and the absence of life-threatening organ failure in cases of HHV-8 positive, HIV negative MCD.

Keywords: Multicentric castleman disease, HHV-8 positive, HIV negative, rituximab, lymphoproliferative, cytokine.

[1]
Fajgenbaum, D.C.; van Rhee, F.; Nabel, C.S. HHV-8-negative, idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis, and therapy. Blood, 2014, 123(19), 2924-2933.
[http://dx.doi.org/10.1182/blood-2013-12-545087] [PMID: 24622327]
[2]
Yu, L.; Tu, M.; Cortes, J.; Xu-Monette, Z.Y.; Miranda, R.N.; Zhang, J.; Orlowski, R.Z.; Neelapu, S.; Boddu, P.C.; Akosile, M.A.; Uldrick, T.S.; Yarchoan, R.; Medeiros, L.J.; Li, Y.; Fajgenbaum, D.C.; Young, K.H. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood, 2017, 129(12), 1658-1668.
[http://dx.doi.org/10.1182/blood-2016-11-748855] [PMID: 28100459]
[3]
Liu, A.Y.; Nabel, C.S.; Finkelman, B.S.; Ruth, J.R.; Kurzrock, R.; van Rhee, F.; Krymskaya, V.P.; Kelleher, D.; Rubenstein, A.H.; Fajgenbaum, D.C. Idiopathic multicentric Castleman’s disease: A systematic literature review. Lancet Haematol., 2016, 3(4), e163-e175.
[http://dx.doi.org/10.1016/S2352-3026(16)00006-5] [PMID: 27063975]
[4]
Soumerai, J.D.; Sohani, A.R.; Abramson, J.S. Diagnosis and management of Castleman disease. Cancer Contr., 2014, 21(4), 266-278.
[http://dx.doi.org/10.1177/107327481402100403] [PMID: 25310208]
[5]
Chan, K.L.; Lade, S.; Prince, H.M.; Harrison, S.J. Update and new approaches in the treatment of Castleman disease. J. Blood Med., 2016, 7, 145-158.
[http://dx.doi.org/10.2147/JBM.S60514] [PMID: 27536166]
[6]
www.uptodate.com HHV-8-associated multicentric Castleman disease. Assessed 13 October 2018.
[7]
Kantarci, F.E.; Eren, R.; Gündoğan, C.; Huq, G.E.; Doğu, M.H.; Suyanı, E.A. HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination. J. Infect. Chemother., 2016, 22(7), 483-485.
[http://dx.doi.org/10.1016/j.jiac.2016.01.002] [PMID: 26948831]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 1
Year: 2020
Page: [84 - 86]
Pages: 3
DOI: 10.2174/1871529X19666190227185318
Price: $65

Article Metrics

PDF: 14
HTML: 2